Cargando…
Efficacy and safety of tacrolimus-based treatment for non-rapidly progressive IgA nephropathy
In this study, we aimed to evaluate the efficacy and safety of tacrolimus-based treatment for immunoglobulin A nephropathy (IgAN). We retrospectively reviewed 127 adult patients with primary IgAN with 24 h urine total protein quantity (24 h UTP) ≥ 1 g and serum creatinine ≤3 mg/dL. All patients were...
Autores principales: | Zhao, Lijuan, Yang, Yanyan, Xu, Hao, Leng, Wei, Xu, Guoshuang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232819/ https://www.ncbi.nlm.nih.gov/pubmed/37274107 http://dx.doi.org/10.3389/fphar.2023.1189608 |
Ejemplares similares
-
Efficacy and Safety of Immunosuppressive Monotherapy Agents for IgA Nephropathy: A Network Meta-Analysis
por: Han, Shisheng, et al.
Publicado: (2021) -
Efficacy and safety of sequential immunosuppressive treatment for severe IgA nephropathy: A retrospective study
por: Luo, Mian-Na, et al.
Publicado: (2023) -
Efficacy and safety of tacrolimus combined with glucocorticoid treatment for IgA nephropathy: a meta-analysis
por: Zhang, Yong, et al.
Publicado: (2018) -
Tacrolimus decreases proteinuria in patients with refractory IgA nephropathy
por: Hu, Tingyang, et al.
Publicado: (2018) -
Tacrolimus Decreases Albuminuria in Patients with IgA Nephropathy and Normal Blood Pressure: A Double-Blind Randomized Controlled Trial of Efficacy of Tacrolimus on IgA Nephropathy
por: Kim, Yong-Chul, et al.
Publicado: (2013)